			Phase 1	Phase 2	Phase 3
Neurology					
valbenazine*	Dyskinetic Cerebral Palsy	VMAT2 Inhibitor			
NBI-921352##	Rare Pediatric Epilepsy: SCN8A-DEE	Na <sub>v</sub> 1.6			
NBI-1076986	Movement Disorders	M4 Antagonist			
Neuroendocrinology					
modified-release hydrocortisone	Adrenal Insufficiency	GC Receptor			
modified-release hydrocortisone	Congenital Adrenal Hyperplasia	GC Receptor			
Neuropsychiatry					
valbenazine*	Adjunctive Treatment of Schizophrenia	VMAT2 Inhibitor			
NBI-1065845¶	Inadequate Response to Treatment in Major Depressive Disorder	AMPA			
NBI-1117568 <sup>††</sup>	Schizophrenia	M4 Agonist			
NBI-1070770¶	Major Depressive Disorder	NMDA NR2B NAM			
NBI-1117570 <sup>††</sup>	CNS Indications	M1/M4 Agonist			
NBI-1117569 <sup>††</sup>	CNS Indications	M4 Preferring Agonist			
NBI-1117567 <sup>††,**</sup>	CNS Indications	M1 Preferring Agonist			
NBI-1065890	CNS Indications	VMAT2 Inhibitor			

SCN8A-DEE = SCN8A Developmental and Epileptic Encephalopathy Syndrome. Neurocrine Biosciences has global rights, unless otherwise noted. Neurocrine Biosciences shares profits and losses on NBI-1065845 with Takeda Pharmaceutical Company Limited.

- \* Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other Company Limited. select Asian markets.
- ## Licensed from Xenon Pharmaceuticals, Inc.

†† Licensed from Nxera Pharma (formerly Sosei Heptares).

\*\* Nxera Pharma (formerly Sosei Heptares) has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.